Literature DB >> 23072543

Five-year outcomes in living donor kidney transplants with a positive crossmatch.

A Bentall1, L D Cornell, J M Gloor, W D Park, M J Gandhi, J L Winters, M F Chedid, P G Dean, M D Stegall.   

Abstract

Renal transplant candidates with high levels of donor-specific anti-HLA antibodies have low transplantation rates and high mortality rates on dialysis. Using desensitization protocols, good short-term outcomes are possible in "positive crossmatch kidney transplants (+XMKTx)", but long-term outcome data are lacking. The aim of the current study was to determine actual 5-year graft outcomes of +XMKTx. We compared graft survival and the functional and histologic status of 102 +XMKTx to 204 -XMKTx matched for age and sex. Actual 5-year death-censored graft survival was lower in the +XMKTx group (70.7% vs. 88.0%, p < 0.01) and chronic injury (glomerulopathy) was present in 54.5% of surviving grafts. Graft survival was higher in recipients with antibody against donor class I only compared with antibody against class II (either alone or in combination with class I) (85.3% vs. 62.6%, p = 0.05) and was similar to -XMKTx (85.3 vs. 88.0%, p = 0.64). Renal function and proteinuria ranged across a wide spectrum in all groups reflecting the different histological findings at 5 years. We conclude that when compared to -XMKTx, +XMKTx have inferior outcomes at 5 years, however, almost half of the surviving grafts do not have glomerulopathy and avoiding antibodies against donor class II may improve outcomes. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2012        PMID: 23072543     DOI: 10.1111/j.1600-6143.2012.04291.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  51 in total

1.  Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use.

Authors:  Jean Kwun; Marie Matignon; Miriam Manook; Soulef Guendouz; Vincent Audard; David Kheav; Elsa Poullot; Chantal Gautreau; Brian Ezekian; Diane Bodez; Thibault Damy; Laureline Faivre; Dehbia Menouch; Janghoon Yoon; Jaeberm Park; Karim Belhadj; Dongfeng Chen; Alyssa M Bilewski; John S Yi; Bradley Collins; Mark Stegall; Alton B Farris; Stuart Knechtle; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2019-06-21       Impact factor: 10.121

2.  Approach to the Highly Sensitized Kidney Transplant Candidate.

Authors:  Douglas S Keith; Gayle M Vranic
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-25       Impact factor: 8.237

3.  Defunctioning polymorphism in the immunoglobulin G inhibitory receptor (FcγRIIB-T/T232) does not impact on kidney transplant or recipient survival.

Authors:  Gerhard Opelz; Kenneth G C Smith; Menna R Clatworthy; Rebeccah J Matthews; Bernd Doehler; Lisa C Willcocks
Journal:  Transplantation       Date:  2014-08-15       Impact factor: 4.939

4.  B cell modulation in transplantation.

Authors:  M R Clatworthy
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 5.  Antibody-incompatible kidney transplantation in 2015 and beyond.

Authors:  Rob M Higgins; Sunil Daga; Dan A Mitchell
Journal:  Nephrol Dial Transplant       Date:  2014-12-13       Impact factor: 5.992

Review 6.  The role of complement in antibody-mediated rejection in kidney transplantation.

Authors:  Mark D Stegall; Marcio F Chedid; Lynn D Cornell
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

7.  Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates.

Authors:  Carrie A Schinstock; Manish Gandhi; Wisit Cheungpasitporn; Donald Mitema; Mikel Prieto; Patrick Dean; Lynn Cornell; Fernando Cosio; Mark Stegall
Journal:  Transplantation       Date:  2017-10       Impact factor: 4.939

8.  Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.

Authors:  Carrie A Schinstock; Andrew J Bentall; Byron H Smith; Lynn D Cornell; Matthew Everly; Manish J Gandhi; Mark D Stegall
Journal:  Am J Transplant       Date:  2018-12-15       Impact factor: 8.086

9.  Of kin and kidneys: do kinship networks contribute to racial disparities in living donor kidney transplantation?

Authors:  Jonathan Daw
Journal:  Soc Sci Med       Date:  2013-12-07       Impact factor: 4.634

10.  Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions.

Authors:  Thomas Bachelet; Lionel Couzi; Vincent Pitard; Xavier Sicard; Claire Rigothier; Sébastien Lepreux; Jean-François Moreau; Jean-Luc Taupin; Pierre Merville; Julie Déchanet-Merville
Journal:  J Am Soc Nephrol       Date:  2014-04-17       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.